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Bulleted statements (max 70 words per question) 
What’s already known about this topic?  
 Bullous pemphigoid is a blistering skin disorder which typically affects the elderly 
 Bullous pemphigoid  poses a high burden on affected patients and has significant 
healthcare costs 
 The burden of disease in the UK was estimated over a decade ago and found a 
rising incidence and high mortality 
What does this study add?  
 The incidence of bullous pemphigoid in England was 7.63 (95%CI 7.35 to 
7.93)/100,000 person-years between 1998-2017.  
 The burden of bullous pemphigoid in the elderly population is substantial and it 
should not be considered a rare disease in these age groups 
 The risk of death was almost three times higher in the first two years after a 
diagnosis of bullous pemphigoid compared to people without the disease and 





A rising incidence and high mortality were found for bullous pemphigoid over a decade 
ago in the UK. Updated estimates of its epidemiology are required to understand the 
healthcare needs of an ageing population. 
Objectives 
To determine the incidence, prevalence, and mortality rates of bullous pemphigoid in 
England from 1998 to 2017.  
Methods 
We conducted a cohort study of longitudinal electronic health records using the Clinical 
Practice Research Datalink and linked Hospital Episode Statistics. Incidence was 
calculated per 100,000 person-years and annual point prevalence per 100,000 people. 
Multivariable analysis was used to determine incidence rate ratios by sociodemographic 
factors. Mortality was examined in an age-, sex-, and practice-matched cohort, using 
linked Office of National Statistics death records. Hazard ratios (HRs) were stratified by 
matched set.  
Results 
The incidence was 7.63 (95%CI 7.35 to 7.93)/100,000 person-years and rose with 
increasing age, particularly for elderly men. The annual increase in incidence was 0.9% 
(95%CI 0.2 to 1.7). The prevalence almost doubled over the observation period, 
reaching 47.99 (95%CI 43.09 to 53.49)/100,000 people and 141.24 (95%CI 125.55 to 
158.87)/100,000 people over the age of 60. The risk of all-cause mortality was highest 
in the two years after diagnosis (HR 2.96; 95%CI 2.68 to 3.26), and remained raised 
thereafter (HR 1.54; 95%CI 1.36 to 1.74). 
Conclusions 
We report a modest increase in the incidence rate of bullous pemphigoid, but show that 
the burden of disease in the elderly population is considerable. Mortality is high, 




Bullous pemphigoid is a rare autoimmune disease, characterised by blistering of the skin. 2 
It is predominantly a disease of the elderly, and is associated with high morbidity, 3 
mortality, and significant healthcare costs.1,2 A previous study of bullous pemphigoid in 4 
the UK estimated that the incidence was increasing by 17% per annum between 1996 5 
and 2006.3 However, this work was conducted over a decade ago and included only 6 
patients identified in primary care. More severe cases whose diagnosis was not returned 7 
to their GP, potentially because they died in hospital shortly after being diagnosed, 8 
would not have been captured. An updated estimate is required to quantify the burden of 9 
disease in England, which may be an important consideration when assessing the 10 
healthcare needs of an ageing population. 11 
Routinely collected electronic healthcare records are valuable for examining a rare 12 
disease like bullous pemphigoid, because of the availability of data on a large number of 13 
patients that are broadly representative of the UK population. Patients with bullous 14 
pemphigoid can be identified using a validated method and code list with a positive 15 
predictive value of 93.2% (95%CI 91.3 to 94.8).4 The incidence and prevalence rates 16 
can be determined with high precision, whilst longitudinal follow-up allows long-term 17 
outcomes, such as death, to be examined. The aim of the present work was to 18 
determine the incidence, prevalence, and mortality of bullous pemphigoid in England 19 
between 1998 and 2017. 20 
Patients and methods 21 
Study design 22 
Incidence and prevalence were examined using a retrospective cohort. An age-, sex-, 23 
and practice-matched longitudinal cohort was used to compare the mortality of bullous 24 
pemphigoid with the general population. We followed RECORD guidelines for reporting of 25 
studies conducted using observational routinely collected health data.5 26 
Data sources 27 
Clinical Practice Research Datalink (CPRD) 28 
The CPRD GOLD is a longitudinal database of UK general practices using the Vision 29 
software system. It contains anonymised healthcare records for approximately 17 million 30 
patients, with a current coverage of approximately 2.7 million (4%) of the UK 31 
population. Routinely collected clinical data generated from consultations, hospital 32 
discharges, or specialist clinic letters are recorded using Read codes.6 Diagnoses of 33 
bullous pemphigoid are predominantly made in secondary care, but are subsequently 34 
returned to GPs and entered into primary care records.  35 
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The data in the CPRD have repeatedly been shown to be of good research quality.7 At a 1 
practice-level, participating practices are assigned an “up-to-standard” date on 2 
completion of regular audits confirming data quality. At the patient-level, records are 3 
assessed and patients are deemed “acceptable” if data checks indicate that their record 4 
meets pre-specified quality standards.  5 
Linked data 6 
Approximately 75% of English practices, covering over 10 million patients, have 7 
consented to provide patient-level information from linked resources.8 Individual-level 8 
linked sources used in this study were Hospital Episode Statistics (HES) admitted patient 9 
care data and Office for National Statistics (ONS) death registration data. HES admitted 10 
patient care contains diagnoses for each hospitalisation episode, coded using the 11 
International Classification of Diseases version 10 (ICD-10).9,10 Death registration data 12 
contain the official date of death. 13 
Study population 14 
Adult men and women registered with 410 HES-linked general practices in England 15 
during the period of 1 January 1998 to 31 December 2017 were included. Patients were 16 
eligible from the date their practice was deemed to be contributing up-to-standard data 17 
and their record was verified as “acceptable” research quality. 18 
Outcomes 19 
For incidence and prevalence, the outcome was a diagnosis of bullous pemphigoid in the 20 
CPRD or HES. The date of death was the outcome for the all-cause mortality analyses. 21 
Case definition of bullous pemphigoid 22 
A diagnosis of bullous pemphigoid is usually made on referral to a dermatology 23 
department, where patients undergo clinical examination and laboratory investigations, 24 
usually a skin biopsy for histology and direct immunofluorescence. The diagnosis is 25 
consequently communicated to primary care, where it is entered in the CPRD using Read 26 
codes, or to the person’s inpatient records, where it is entered in the HES admitted 27 
patient care records using ICD-10 codes.  28 
People with bullous pemphigoid were adult patients with a diagnostic code for bullous 29 
pemphigoid in the CPRD or HES. An algorithm was applied to the CPRD to identify 30 
patients with Read codes for bullous pemphigoid (M145000, “bullous pemphigoid”; 31 
M145.00, “pemphigoid”; or M145z00, “pemphigoid not otherwise specified”).4 A similar 32 
algorithm, using ICD-10 diagnostic codes, was applied to HES admitted patient care data 33 
(L12.0 “bullous pemphigoid” or L12.9 “pemphigoid, unspecified”). The index date of 34 
diagnosis for people with bullous pemphigoid was the first date of occurrence of the Read 35 
or ICD-10 code generated from the algorithm. 36 
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Incident diagnoses were those with an index date at least one year after their current 1 
registration date with their GP. The 1-year lag period was imposed to minimise the risk 2 
of prevalent cases being identified as incident ones.11 Prevalent diagnoses were those 3 
with a record of bullous pemphigoid at any point before the end of the observation 4 
period. 5 
Matched disease-free individuals 6 
Up to four disease-free unexposed individuals were selected randomly for each case and 7 
matched by age (within one year of date of birth), sex, and general practice. They were 8 
assigned an index date, which was the date of diagnosis of bullous pemphigoid of the 9 
case they were matched to. The matched disease-free individuals had to be alive and 10 
contributing data at the time of the index date. 11 
Observation period 12 
The observation period commenced on the latest of (i) 1st January 1998, (ii) the date the 13 
patient registered with their current practice, (iii) the practice’s up-to-standard date, or 14 
(iv) the patient's 18th birthday. 15 
The observation period terminated on the earliest of (i) 31st December 2017, (ii) the 16 
date of death, (iii) the date the patient left the practice, (iv) the practice’s last data 17 
collection date, or (v) the most recent linkage date between CPRD and HES.  18 
Statistical analysis 19 
Incidence 20 
The incidence rates per 100,000 person-years overall and by age (10-year bands), 21 
calendar period (three-year bands), sex, ethnicity, region, and index of multiple 22 
deprivation were calculated. Poisson regression was used to determine incidence rate 23 
ratios for each sociodemographic factor. For the unordered categorical factors region and 24 
ethnicity, the group with the most person-years of follow-up was chosen as the 25 
reference category. Multivariable regression was used to adjust for age, sex, and 26 
calendar period. A post-hoc examination of the interaction between age and sex, 27 
adjusted for calendar period, was conducted.  28 
The crude, age- and sex-adjusted annual change in incidence was determined over the 29 
20-year observation period. The crude incidence rate for each calendar year, with direct 30 
standardisation to the European Standard Population of 2013, was determined.  31 
Annual point prevalence 32 
The number of individuals with bullous pemphigoid contributing data on the 31st of July 33 
of each calendar year were divided by the total number of adults alive and contributing 34 




People with bullous pemphigoid and their matched disease-free individuals were followed 2 
from their index date, and all deaths in the cohort were identified. Crude mortality rates 3 
were calculated per 1,000 person-years. Kaplan-Meier techniques were used to 4 
determine one-year mortality and median survival time. All-cause mortality in people 5 
with versus without bullous pemphigoid was compared using Cox proportional hazards 6 
regression stratified by matched set to account for age, sex, general practice, and 7 
calendar period. The proportional hazards assumption, tested using Schoenfeld’s 8 
residual, was violated. The observation period was therefore divided into two follow-up 9 
periods: within two years and two years or more after the index date. 10 
Study size 11 
This was a population-based cohort study that used all available data. Assuming only 12 
one matched disease-free individual was found per patient with bullous pemphigoid, this 13 
study would have >90% power to detect a hazard ratio of 2.1 or greater at the 5% 14 
significance level. 3  15 
Sensitivity analyses 16 
The incidence, prevalence, and mortality of bullous pemphigoid in the UK were 17 
established using all primary care data available in the CPRD, irrespective of linkages. 18 
The results were compared to the primary analyses, which included only patients 19 
registered with HES-linked practices. Incidence rate ratios for ethnicity were only 20 
determined after 2006 as ethnicity data were more poorly recorded for people who 21 
registered with the CPRD prior to this.12  22 
Unless otherwise specified, p-values presented were obtained from the likelihood ratio 23 
test and p<0.05 was considered statistically significant. Analyses were conducted with 24 
Stata 16 (StataCorp. 2019). 25 
Ethical approval 26 
The present study was approved by the Independent Scientific Advisory Committee for 27 
the CPRD (ISAC protocol no 18_224).  28 
Results 29 
Study population 30 
2,658 incident individuals with bullous pemphigoid were identified during the observation 31 
period: 2,468 from English HES-linked general practices in the CPRD (Figure 1) and an 32 
additional 190 individuals with a diagnosis of bullous pemphigoid only in their HES 33 
records. Median age at presentation was 81 (interquartile range 72 to 87) years, and 34 
1,497 (56.3%) of patients were women.  35 
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Incidence  1 
The pooled incidence rate over the 20-year period was 7.63 (95%CI 7.35 to 2 
7.93)/100,000 person-years (Table 1). The crude incidence rate was 25% higher in 3 
women (rate ratio [RR] 1.25, 95%CI 1.16 to 1.35), but after adjustment for age and 4 
calendar period, the incidence rates were 13% lower in women (RR 0.87, 95%CI 0.80 to 5 
0.94) than men. Incidence rates rose dramatically with age, such that the highest rates 6 
were recorded in patients over 90 years. The increase in incidence in older age groups 7 
was more marked for men than women (p-value for interaction <0.001, Figure 2). After 8 
adjustment for age, sex, and calendar period, rates were highest in those of Asian 9 
ethnicity and lowest in those of unknown ethnicity than Whites, but ethnicity data were 10 
missing in 26% of the whole study population. Incidence varied by geographic region, 11 
but not by level of deprivation.  12 
Between 1998 and 2017, incidence increased by 1.2% (rate ratio: 1.012; 95%CI 1.005 13 
to 1.020; p=0.002) per calendar year. After adjustment for age and sex, the estimated 14 
annual increase in incidence was 0.9% (rate ratio: 1.009; 95%CI 1.002 to 1.017; 15 
p=0.016). Overall increase in incidence over the 20-year study period (2017 versus 16 
1998) was 16.4% after adjustment for age and gender (rate ratio: 1.164; 95%CI 0.805 17 
to 1.684; p=0.420). Annual incidence rates, calculated by direct standardisation to the 18 
European Standard Population, are illustrated in Supporting Figure 1.  19 
Prevalence 20 
The prevalence of bullous pemphigoid was 26.82 (95%CI 23.83 to 30.19)/100,000 21 
people in 1998 and increased to 47.99 (95%CI 43.09 to 53.46)/100,000 in 2017 (Figure 22 
3). The most recent estimate of the prevalence of bullous pemphigoid in those aged over 23 
60 years was 141.24 (95%CI 125.55 to 158.87)/100,000 people in 2017. In the over-24 
80s, the prevalence was 375.02 (95%CI 320.31 to 439.04)/100,000.  25 
Mortality 26 
The cohort included 2,639 people with bullous pemphigoid and 10,463 matched disease-27 
free individuals (details provided in Supporting Information). Within the cohort 1,237 28 
deaths occurred in the individuals with bullous pemphigoid and 3,427 in those without, 29 
equating to a crude mortality rate (per 1,000 person-years) of 138.82 (95%CI 131.30 to 30 
146.78) for people with bullous pemphigoid and 74.56 (95%CI 72.11 to 77.10) for 31 
people without. The median survival time was 4.93 years for people with bullous 32 
pemphigoid and 9.27 years for people without (Figure 4). One-year mortality for bullous 33 
pemphigoid was 20.36% (95%CI 18.82 to 22.00) and 7.03% (95%CI 6.54 to 7.55) for 34 
disease-free individuals.  35 
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After stratifying by matched set to account for age, gender, and general practice, the HR 1 
was 2.96 (95%CI 2.68 to 3.26) in the first two years and 1.54 (95%CI 1.36 to 1.74) 2 
thereafter. 3 
Sensitivity analyses 4 
All results were confirmed in sensitivity analyses using patients from all of the CPRD 5 
compared with the main analysis, which examined HES-linked practices only (Supporting 6 
Information). 7 
Discussion 8 
Main findings 9 
The incidence of bullous pemphigoid during the 20-year observation period was 7.63 10 
(95%CI 7.35 to 7.93)/100,000 person-years. The incidence was highest in the elderly, 11 
particularly in elderly men. Between 1998 to 2017, the incidence of bullous pemphigoid 12 
increased by 0.9% (95%CI 0.2 to 1.7) per calendar year and the prevalence almost 13 
doubled from 26.82 (95%CI 23.83 to 30.19)/100,000 people in 1998 to 47.99 (95%CI 14 
43.09 to 53.46)/100,000 people in 2017. Using the European definition of a rare disease 15 
(prevalence <50 per 100,000 people),13 we have for the first time shown that bullous 16 
pemphigoid is not a rare disease in the elderly (≥60 years). 17 
The risk of death within two years of diagnosis was almost three times higher in patients 18 
with bullous pemphigoid than in matched disease-free individuals (HR 2.96, 95%CI 2.68 19 
to 3.26). The mortality remained raised throughout the remainder of the observation 20 
period (HR 1.54, 95%CI 1.36 to 1.74). 21 
Comparability with other studies 22 
Incidence and prevalence 23 
An increasing incidence of bullous pemphigoid has previously been reported in the UK 24 
using data from The Health Improvement Network (THIN) up to 2006.3 The current data 25 
shows a more modest increase in incidence over time, but a higher incidence rate across 26 
the whole observation period. The reasons for these differences are likely multifactorial, 27 
although largely driven by differences between the databases used. Significantly lower 28 
incidence rates have been reported for venous leg ulcers in THIN compared to the 29 
General Practice Research Database (GPRD; the predecessor of CPRD) using data 30 
collected pre-2000.14 The low incidence rate of bullous pemphigoid observed using THIN, 31 
particularly prior to 1998, may be artefactual and could explain why a more dramatic 32 
increase in incidence over time was found. Other factors that may explain the 33 
discrepancy include small differences in either the numerator or denominator between 34 
the present and the earlier study. For example, the present study used an algorithm to 35 
identify patients and included patients that had records of bullous pemphigoid in HES, 36 
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but not CPRD. Nevertheless, the absolute difference in incidence between the studies 1 
remains small and reduces over time. 2 
Our incidence results are similar to those reported recently in Sweden.15 Using the 3 
National Patient Register the authors reported an incidence of 7.1 (95%CI 6.5 to 4 
7.7)/100,000 person-years.15 In contrast, studies conducted elsewhere in the world 5 
report lower results (Supporting Table 3).16-28 This may be due to underlying differences 6 
in risk between populations or because of differences in methods. For example, other 7 
studies generally present rates for the population including children, who are rarely 8 
affected. In addition, other studies are generally smaller, hospital-based, and may not 9 
achieve complete capture of all cases within the defined denominator as patients 10 
managed in primary care or referred to other dermatology centres outside the 11 
geographical boundaries of the study are often missed. 12 
Mortality 13 
The one-year mortality of 20.36% in present study is similar to previous estimates from 14 
the UK, Between 1996 and 2006, the one-year mortality in the UK using THIN was 19% 15 
(95%CI 16.2 to 21.8).3 Between 1991 and 2001 the one-year mortality of the 83 16 
incident cases identified from the Pathology and Immunology database of a single 17 
referral centre in North-east Scotland was 25%.23 A recent meta-analysis estimated the 18 
pooled one-year mortality rate in European populations to be 26.7% (95%CI 22.2% to 19 
31.2%), although the heterogeneity between studies was large.29 Survival in the first 20 
year after diagnosis appears marginally better in England than the rest of Europe, but 21 
worse than the USA (15.1%, 95%CI 7.9 to 22.3%). Such differences in mortality could 22 
be explained by differences between populations, methods of case and outcome 23 
ascertainment, temporal trends, or true differences in the mortality between nations. 24 
Strengths and limitations 25 
The strengths of this study include a large sample size, a population that is 26 
representative of the UK general population, use of a validated approach to identify 27 
cases, accurate recording of death dates, and using linked primary and secondary care 28 
data to get a more comprehensive coverage of cases. Using routinely recorded data on a 29 
population level makes this study less susceptible to selection bias. 30 
Case ascertainment is a limitation as it is reliant on the presence of clinical codes 31 
indicative of bullous pemphigoid. Inaccurate recording may have affected the estimates. 32 
We know from previous work that a small proportion of those identified with bullous 33 
pemphigoid codes are likely to have other diagnoses, such as mucous membrane 34 
pemphigoid.4 Inversely, some patients with bullous pemphigoid may be missed as they 35 
are coded as having pemphigus vulgaris. However, the positive predictive value of the 36 
bullous pemphigus codes in this study is 93%, supporting our conclusions. Additionally, 37 
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it is difficult to interpret findings related to ethnicity due to poor recording in those 1 
registered pre-2006. Finally, our work has assumed that once a patient has developed 2 
bullous pemphigoid they remain a prevalent case until the end of follow-up. In reality, 3 
patients may enter remission or become disease-free, and the true prevalence of bullous 4 
pemphigoid may be more conservative than that presented.  5 
Possible explanations for findings 6 
The incidence of bullous pemphigoid rises with increasing age, which may reflect an 7 
aetiology related to the biological process of ageing. This effect was more marked in 8 
men. An alternative explanation may be the age-related rise in prevalence of diseases 9 
associated with the development of bullous pemphigoid, such as dementia and 10 
Parkinson’s.30,31 Alternatively, the relationship may reflect increasing use of drugs that 11 
induce bullous pemphigoid in the elderly population. Variation in the incidence of bullous 12 
pemphigoid was also observed between ethnic groups and geographic regions. The anti-13 
diabetic drug DPP4-i is associated with approximate doubling of the risk of bullous 14 
pemphigoid32-36 and the increased risk in Asians, compared to the white ethnic group, 15 
may partly relate to the increased levels of diabetes in this ethnic group. The rising trend 16 
for prescriptions of DPP4-i for diabetes throughout the study period may also contribute 17 
to the increased incidence observed.37,38 Regional differences could point to 18 
environmental factors, perhaps to differences in incidence between urban and rural 19 
communities,18 or could be due to differences in the prescribing patterns or awareness of 20 
bullous pemphigoid in the medical communities. The rising prevalence of bullous 21 
pemphigoid may be a result of the increasing incidence of the disease or may reflect that 22 
the English population is living longer.39 Alternatively, it may be that the prevalence 23 
nearer the date of database inception may be underestimated. People with diagnoses 24 
prior to the inception of CPRD may not have had the disease entered retrospectively into 25 
their electronic records. 26 
Possible clinical implications of the findings 27 
Healthcare professionals should be made aware that bullous pemphigoid is not a rare 28 
disease in the elderly. A greater awareness of the disease will hopefully reduce 29 
diagnostic delay. The mortality risk from bullous pemphigoid has remained largely 30 
unchanged since it was last examined over a decade ago. Improved management, a 31 
better understanding of the aetiology, and examination of the causes of death in bullous 32 
pemphigoid are still required.  33 
Conclusion 34 
Bullous pemphigoid is a rising concern for the ageing population of England. In the 35 
elderly populations, it should no longer be considered a rare disease. Its incidence 36 
increases with age and it is associated with almost three times greater chance of death 37 
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in the first two years after diagnosis compared to disease-free individuals. The increased 1 
burden of disease, particularly in the elderly, requires earlier diagnosis, improved 2 
treatment, and better understanding of the aetiology. 3 
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Figure legends 1 
Figure 1. Algorithm used to identify incident adult individuals with bullous pemphigoid in 2 
the CPRD between January 1998 and December 2017  3 
Figure 2. Crude incidence rate of bullous pemphigoid in English HES-linked general 4 
practices and hospital inpatient records per 100,000 person years per age category. 5 
Rates shown separately for men and women, with upper and lower limits of 95%CI 6 
Figure 3. Point prevalence of bullous pemphigoid on 31st of July of each calendar year in 7 
English HES-linked general practices, per 100,000 people. Prevalence rates shown for all 8 
adults and for people aged over 60 years, with shading indicating the upper and lower 9 
limits of the 95%CI 10 
Figure 4. Kaplan-Meier curve for patients with and without bullous pemphigoid, showing 11 
mortality over time since index date and number of patients remaining in the study  12 
  13 
Adult patients with a CPRD diagnosis of bullous pemphigoid
January 1998 to December 2017
n = 4,842
Incident cases with a CPRD diagnosis of bullous pemphigoid




Patients with a CPRD diagnosis of bullous pemphigoid
n = 7,967
Adult patients with a CPRD diagnosis of bullous pemphigoid
n = 7,862
Patients <18 years of age on index date
n = 105
Patients with index date outside observation period
n = 3,020
Patients with index date within 12 months of
current registration date
n = 405
Incident cases of bullous pemphigoid from HES-linked practices
n = 2,468
Incident cases identified only in HES
n = 190
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Table 1. Univariate and multivariable analysis of incidence of bullous pemphigoid in 2 
HES-linked general practices and hospital inpatient records in England per 100,000 3 
person years.  4 
Variable 
Person 
years Events Incidence rate Crude rate ratio p value 
Mutually adjusted 
incidence rate ratios p value 
Pooled 34,825,210 2,658 7.63 (7.35 to 7.93) -  -  
        
Gender     <0.001  <0.001 
Male 17,171,950 1,161 6.76 (6.38 to 7.16) 1.00  1.00  
Female 17,653,250 1,497 8.48 (8.06 to 8.92) 1.25 (1.16 to 1.35)  0.87 (0.80 to 0.94)  
        
Age group 
(years) 
    <0.001*  <0.001* 
<60 24,467,650 254 1.04 (0.92 to 1.17) 1.00  1.00  
60-69 4,765,380 264 5.54 (4.91 to 6.25) 5.34 (4.49 to 6.34)  5.34 (4.49 to 6.34)  
70-79 3,423,240 662 19.34 (17.92 to 20.87) 18.63 (16.12 to 21.53)  18.79 (16.26 to 21.72)  
80-89 1,812,280 1,074 59.26 (55.82 to 62.92) 57.09 (49.79 to 65.45)  58.12 (50.67 to 66.67)  
≥90 356,660 404 113.27 (102.75 to 
124.88) 
109.12 (93.27 to 
127.66) 
 112.88 (96.36 to 132.23)  
        
Calendar year 
(years) 
    0.007*  0.049* 
1998-2000 3,702,250 247 6.67 (5.89 to 7.56) 1.00  1.00  
2001-2003 5,543,890 405 7.31 (6.63 to 8.05) 1.10 (0.94 to 1.28)  1.07 (0.91 to 1.26)  
2004-2006 6,288,600 470 7.47 (6.83 to 8.18) 1.12 (0.96 to 1.31)  1.09 (0.94 to 1.28)  
2007-2009 6,605,740 508 7.69 (7.05 to 8.39) 1.15 (0.99 to 1.34)  1.12 (0.96 to 1.30)  
2010-2012 6,369,500 534 8.38 (7.70 to 9.13) 1.26 (1.08 to 1.46)  1.20 (1.03 to 1.40)  
2013-2015 4,745,980 363 7.65 (6.90 to 8.48) 1.15 (0.98 to 1.35)  1.08 (0.92 to 1.27)  
2016-2017 1,569,240 131 8.35 (7.03 to 9.91) 1.25 (1.01 to 1.55)  1.21 (0.98 to 1.50)  
        
Ethnicity     <0.001  <0.001 
White 23,950,960 2,318 9.68 (9.29 to 10.08) 1.00  1.00  
Black† 484,490 14 2.89 (1.71 to 4.88) 0.30 (0.18 to 0.51) <0.001 0.80 (0.48 to 1.36) 0.415 
Asian† 965,200 47 9.65 (3.66 to 6.48) 0.50 (0.38 to 0.67) <0.001 1.37 (1.03 to 1.84) 0.033 
Other† 418,380 23 5.50 (3.65 to 8.27) 0.57 (0.38 to 0.86) 0.007 1.22 (0.81 to 1.84) 0.347 
Unknown† 9,006,180 256 2.84 (2.52 to 3.21) 0.29 (0.26 to 0.33) <0.001 0.63 (0.55 to 0.72) <0.001 
        
Region      <0.001  0.020 
North West 5,374,400 359 6.68 (6.02 to 7.41) 1.00  1.00  
North East 799,330 43 5.38 (3.99 to 7.25) 0.81 (0.59 to 1.11)  0.81 (0.59 to 1.11)  
Yorkshire & The 
Humber 
1,402,950 100 7.13 (5.86 to 8.67) 1.07 (0.86 to 1.33)  1.02 (0.82 to 1.28)  
East Midlands 1,052,510 65 6.18 (4.84 to 7.88) 0.93 (0.71 to 1.20)  0.95 (0.73 to 1.24)  
West Midlands 4,254,880 307 7.22 (6.45 to 8.07) 1.08 (0.93 to 1.26)  0.99 (0.85 to 1.15)  
East of England 4,007,770 316 7.89 (7.06 to 8.80) 1.18 (1.02 to 1.37)  1.12 (0.96 to 1.30)  
South West 4,355,830 430 9.87 (8.98 to 10.85) 1.48 (1.29 to 1.70)  1.20 (1.04 to 1.38)  
South Central 4,543,990 377 8.30 (7.50 to 9.18) 1.24 (1.08 to 1.44)  1.14 (0.99 to 1.32)  
London 4,352,770 308 7.08 (6.33 to 7.91) 1.06 (0.91 to 1.23)  1.15 (0.99 to 1.34)  
South East Coast 4,680,780 353 7.54 (6.79 to 8.37) 1.13 (0.98 to 1.31)  0.99 (0.85 to 1.14)  
        
Deprivation     0.005*  0.208* 
1 8,312,070 657 7.90 (7.32 to 8.53) 1.00  1.00  
2 7,702,910 601 7.80 (7.20 to 8.45) 0.99 (0.88 to 1.10)  0.94 (0.84 to 1.05)  
3 7,260,820 610 8.40 (7.76 to 9.10) 1.06 (0.95 to 1.19)  1.02 (0.91 to 1.14)  
4 6,272,660 438 6.98 (6.36 to 7.67) 0.88 (0.78 to 1.00)  0.91 (0.80 to 1.02)  
5 5,276,750 352 6.67 (6.01 to 7.41) 0.84 (0.74 to 0.96)  0.93 (0.81 to 1.06)  
*LR test for trend; †Wald’s test; all other p-values are from LR test 




Table 2. HR for death, stratified by matched set, comparing patients with bullous 2 
pemphigoid and matched disease-free people from HES-linked general practices and 3 
hospital inpatient records in England. Mortality rates are presented per 1,000 person-4 
years 5 
Variable Person years Events Mortality rate (95%CI) Stratified HR* (95%CI) p value 
Pooled**      
Controls 45,961.5 3,427 74.56 (72.11 to 77.10) -  
Cases 8,910.7 1,237 138.82 (131.30 to 146.78)   
      
<2 years      
Controls 17,374.5 1,270 73.10 (69.18 to 77.23) 1.00 <0.001 
Cases 3,759.0 734 195.26 (181.64 to 209.91) 2.96 (2.68 to 3.26)  
      
≥2 years      
Controls 28,578.0 2,157 75.45 (72.34 to 78.71) 1.00 <0.001 
Cases 5,151.7 503 97.64 (89.47 to 106.55) 1.54 (1.36 to 1.74)  
*HR stratified by matched set to account for age, sex, general practice, and calendar period 




Supporting Figure 1  
Age-adjusted incidence rate of bullous pemphigoid in English HES-linked general 
practices and hospital inpatient records per 100,000 person years by calendar year, with 
direct standardisation to the 2013 European standard population. Shown with upper and 
lower limits of the 95% confidence interval 
 
Supporting Text 1 - Details of matching individuals with and without bullous 
pemphigoid for mortality analyses 
No matched disease-free individual was found for 19 of the 2,658 incident people with 
bullous pemphigoid and these were dropped. Of those dropped, 9 (47.4%) were women 
and the median age was 97 years (range 90-105). Ten (0.4%) people with bullous 
pemphigoid were matched to one disease-free person, 15 (0.6%) were matched to two 
disease-free people, 33 (1.3%) were matched to three disease-free people, and 2,581 
(97.8%) were matched to four disease-free people.  
Supporting Text 2 - Incidence sensitivity analysis 
Sensitivity analysis including data from all general practices in the CPRD, irrespective of 
linkage. In general, the incidence rates of BP were lower in all of CPRD than in HES-
linked general practices and HES admitted patient care data. As for the HES-linked data, 
people with a recorded Asian ethnicity had a higher incidence of BP than people of white 
ethnicity, after adjusting for age and gender. However, no significant difference in 
incidence according to ethnicity overall (including unknown ethnicity) was found.  
The estimated increase in incidence of bullous pemphigoid per calendar year was 1.1% 
(rate ratio: 1.011; 95%CI 1.005 to 1.017; p<0.001). After adjustment for age and 
gender, the estimated annual increase in incidence was 0.7% (rate ratio: 1.007; 95%CI 
1.002 to 1.013; p=0.014).  
Supporting Table 1. Univariate and multivariate analysis of incidence of bullous 
pemphigoid in UK primary care per 100,000 person years  
Variable 
Person 
years Events Incidence rate Crude rate ratio p value 
Mutually adjusted 
incidence rate ratios p value 
Pooled 67,904,270 4,437 6.53 (6.35 to 6.73) - - - - 
        
Gender     <0.001  0.004 
Male 33,458,760 1,901 5.68 (5.43 to 5.94) 1.00  1.00  
Female 34,445,510 2,536 7.36 (7.08 to 7.66) 1.30 (1.22 to 1.38)  0.92 (0.86 to 0.97)  
        
Age group 
(years) 
    <0.001*  <0.001* 
<60 47,956,440 455 0.95 (0.87 to 1.04) 1.00  1.00  
60-69 9,312,340 460 4.94 (4.51 to 5.41) 5.21 (4.57 to 5.93)  5.20 (4.57 to 5.92)  
70-79 6,568,890 1,174 17.87 (16.88 to 18.92) 18.84 (16.91 to 20.99)  18.95 (17.00 to 21.11)  
80-89 3,385,560 1,731 51.13 (48.78 to 53.59) 53.89 (48.60 to 59.75)  54.46 (49.11 to 60.41)  
≥90 681,030 617 90.60 (83.72 to 98.04) 95.49 (84.60 to 107.78)  97.47 (86.27 to 110.14)  
        
Calendar year 
(years) 
    0.001*  0.032* 
1998-2000 6,319,640 360 5.70 (5.14 to 6.32) 1.00  1.00  
2001-2003 9,750,800 582 5.97 (5.50 to 6.47) 1.05 (0.92 to 1.20)  1.04 (0.91 to 1.18)  
2004-2006 11,946,450 785 6.57 (6.13 to 7.05) 1.15 (1.02 to 1.31)  1.15 (1.01 to 1.30)  
2007-2009 12,387,440 824 6.65 (6.21 to 7.12) 1.17 (1.03 to 1.32)  1.15 (1.01 to 1.30)  
2010-2012 12,142,060 861 7.09 (6.63 to 7.58) 1.25 (1.10 to 1.41)  1.20 (1.06 to 1.36)  
2013-2015 10,497,290 695 6.62 (6.15 to 7.13) 1.16 (1.02 to 1.32)  1.10 (0.97 to 1.25)  
2016-2017 4,860,560 330 6.79 (6.10 to 7.56) 1.19 (1.03 to 1.38)  1.13 (0.98 to 1.31)  
        
Ethnicity†     <0.001  0.075 
White 18,203,480 1,248 6.86 (6.49 to 7.25) 1.00  1.00  
Black†† 386,250 9 2.33 (1.21 to 4.48) 0.34 (0.18 to 0.66) 0.001 0.78 (0.41 to 1.50) 0.459 
Asian†† 914,550 40 4.37 (3.21 to 5.96) 0.64 (0.47 to 0.87) 0.005 1.51 (1.10 to 2.06) 0.011 
Other†† 454,560 9 1.98 (1.03 to 3.81) 0.29 (0.15 to 0.56) <0.001 0.75 (0.39 to 1.45) 0.396 
Unknown†† 23,977,400 1,685 7.03 (6.70 to 7.37) 1.03 (0.95 to 1.10) 0.508 0.96 (0.90 to 1.04) 0.330 
        
Region      <0.001  <0.001 
North West 6,906,360 415 6.01 (5.46 to 6.62) 1.00  1.00  
North East 995,670 59 5.93 (4.59 to 7.65) 0.99 (0.75 to 1.30)  0.98 (0.74 to 1.28)  
Yorkshire & The 
Humber 
1,906,140 122 6.40 (5.36 to 7.64) 1.07 (0.87 to 1.30)  1.02 (0.83 to 1.24)  
East Midlands 1,958,890 119 6.08 (5.08 to 7.27) 1.01 (0.83 to 1.24)  1.02 (0.83 to 1.25)  
West Midlands 5,869,540 383 6.53 (5.90 to 7.21) 1.09 (0.95 to 1.25)  1.02 (0.89 to 1.17)  
East of England 5,054,400 342 6.77 (6.09 to 7.52) 1.13 (0.98 to 1.30)  1.08 (0.93 to 1.24)  
South West 5,181,450 449 8.67 (7.90 to 9.51) 1.44 (1.26 to 1.65)  1.20 (1.05 to 1.38)  
South Central 6,427,040 481 7.48 (6.84 to 8.18) 1.25 (1.09 to 1.42)  1.15 (1.01 to 1.32)  
London 5,797,220 367 6.33 (5.72 to 7.01) 1.05 (0.92 to 1.21)  1.13 (0.98 to 1.30)  
South East Coast 6,436,140 458 7.12 (6.49 to 7.80) 1.18 (1.04 to 1.35)  1.02 (0.89 to 1.16)  
Northern Ireland 2,768,540 170 6.14 (5.28 to 7.14) 1.02 (0.86 to 1.22)  1.11 (0.92 to 1.32)  
Scotland 9,928,620 494 4.98 (4.56 to 5.43) 0.83 (0.73 to 0.94)  0.87 (0.76 to 0.99)  
Wales 8,674,260 578 6.66 (6.14 to 7.23) 1.11 (0.98 to 1.26)  0.99 (0.87 to 1.12)  
*LR test for trend; †† Wald’s test; all other p-values are from LR test 
†Ethnicity was examined in data from 2006-2018 only 
Mutually adjusted model is adjusted for age, gender, and calendar year 
 
Supporting Text 3 – Prevalence sensitivity analysis  
Using data from all of the CPRD, irrespective of linkages, the prevalence of bullous 
pemphigoid was 25.19 (95%CI 22.97 to 27.62) per 100,000 people in 1998 and rose to 
43.13 (95%CI 40.60 to 45.81) in 2017. The trend in prevalence during the observation 
period is shown in Supporting Figure 2.  
Supporting Figure 2. Point prevalence of bullous pemphigoid on 31st of July of each 
calendar year in all of the CPRD, per 100,000 people. Prevalence rates shown for all 
adults and for people aged over 60 years, with shading indicating the upper and lower 
limits of the 95%CI 
 
 
Supporting Text 4 – Mortality sensitivity analysis  
The mortality rate was examined using data from all of the CPRD, using the death dates 
recorded in the CPRD. No matched disease-free individual was found for 25 of the 4,437 
incident people with bullous pemphigoid and were dropped. The cohort analysed 
consisted of 4,412 people with bullous pemphigoid and 17,519 matched disease-free 
people. 21 (0.5%) people with bullous pemphigoid were matched only to one disease-
free person, 17 (0.4%) were matched to two disease-free people, 32 (0.7%) were 
matched to three disease-free people, and 4,342 (98.4%) were matched to four disease-
free people.  
Within the cohort 2,059 deaths occurred in those with bullous pemphigoid and 5,713 in 
those without bullous pemphigoid, equating to a crude mortality rate (per 1,000 person-
years) of 107.98 (95%CI 103.41 to 112.74) for patients with bullous pemphigoid and 
71.91 (95%CI 70.07 to 73.80) for patients without disease. The median survival time 
was 6.21 years for individuals with and 9.64 years for individuals without bullous 
pemphigoid (Supporting Figure 3). 
After stratifying by matched set to account for age, gender, and general practice, 
mortality was raised for people with bullous pemphigoid compared to matched people 
without bullous pemphigoid both in the first two years after diagnosis (HR 2.64; 95%CI 
2.44 to 2.85) and in the subsequent years (HR 1.67; 1.52 to 1.83).  
Supporting Table 2. HR for death, stratified by matched set, comparing patients with 
bullous pemphigoid and matched disease-free people from general practices in the UK. 
Mortality rates are presented per 1,000 person-years 
Variable Person years Events Mortality rate (95%CI) Stratified HR* (95%CI) p value 
Pooled**      
Controls 79,445.2 5,713 71.91 (70.07 to 73.80) - - 
Cases 19,068.8 2,059 107.98 (103.41 to 112.74)   
      
<2 years      
Controls 29,172.7 2,097 71.88 (68.87 to 75.03) 1.0 <0.001 
Cases 6,723 1,176 174.92 (165.20 to 185.21) 2.64 (2.44 to 2.85)  
      
≥2 years      
Controls 50,272.5 3,616 71.93 (69.62 to 74.31) 1.00 <0.001 
Cases 12,345.8 883 71.52 (66.96 to 76.40) 1.67 (1.52 to 1.83)  
*Stratified by matched set to account for age, sex, general practice, and calendar period 
**Adjusted HR not calculated for the pooled follow-up period the proportional hazards assumption was violated 
 
Supporting Figure 3. Kaplan-Meier curve showing mortality over time since diagnosis 
of bullous pemphigoid or index date in disease-free individuals in all CPRD practices. 
Censoring indicated by “+” and the number of patients remaining in the study are given 
 
 
Supporting Table 3 
Supporting Table 3. Published studies reporting the incidence or prevalence of bullous pemphigoid 
Study Incidence/prevalence 
per 100,000 (95%CI) 
Country Years Design Setting of cases Denominator source 
Incidence       
Present study 7.63 (7.35 to 7.93) England 1998-2017 Retrospective Diagnostic code within the CPRD; routinely 
collected primary healthcare data 
Adult population at risk within 
database 
Nanda 2004 0.205 Kuwait 1991-2002 Not stated New cases registered for the autoimmune 
bullous disease clinic of a tertiary 
dermatology centre  
Unclear (estimate is for 50% of 
country’s population) 
Jung 1999 0.61 (0.22 to 1.30) Germany 1989-1997 Retrospective Diagnosis recorded in the discharge notes of 
two dermatology departments 
Statistische Bundesamt 
Serwin 2014 0.738 (0.535 to 0.941) Poland 1999-2012 Retrospective Cases hospitalised in the dermatology 
department of two hospitals 
Central Statistical Office 
Wong 2002 0.76 Singapore 1998-1999 Retrospective Cases diagnosed in a tertiary referral centre Unclear (estimate is for 
catchment area) 
Kridin 2018 1.14 (1.02 to 1.29) Israel 2000-2015 Retrospective Diagnosis made within a tertiary 
dermatology centre 
2008 census 
Marazza 2009 1.21 (1.01 to 1.41)c Switzerland 2001-2002 Prospective Newly diagnosed cases identified from data 
collection forms circulated to all dermatology 
clinics and specialised laboratories 
Federal Statistical Office 
Bertram 2009 1.34 Germany 2001-2002 Prospective Newly diagnosed cases presenting to a single 
dermatology department 
Bavarian State Office for 
Statistics and Data Processing  
Gudi 2005 1.4 Scotland 1991-2001 Retrospective Diagnosis recorded in the Pathology and 
Immunology database of a hospital 
Community Health Index 
Försti 2014 1.7 (1.5 to 2.0)b 
 
Finland 1985-2009 Retrospective Diagnosis recorded in the hospital database, 
with review of medical notes 
Statistics Finland 
Joly 2012 2.17 (1.98 to 2.37) France 2000-2005 Retrospective Diagnosis recorded in the pathology 
laboratories of several hospitals and private 
practices 
French National Institute of 
Statistics and Economic Studies  
Cordel 2009 2.33 (1.55 to 3.42) Guadeloupe 2006-2009 Prospective Cases diagnosed by eight dermatologists (7 
private practice, 1 hospital-based) 
French National Institute of 
Statistics and Economic Studies 
Brick 2014 2.4 (1.9 to 2.9)a USA 1960-2009 Retrospective Diagnosis recorded in medical records 
(within Rochester Epidemiology Project) 
Census (up to 2000) and from  
US Intercensal Estimates for 
2001-2009 
Langan 2008 4.28 (4.01 to 4.58) UK 1996-2006 Retrospective Diagnostic code within The Health 
Improvement Network  (THIN); routinely 
collected primary healthcare data 




6.6 (6.0 to 7.2)d Sweden  2005-2012 Retrospective Diagnostic code (inpatient or outpatient) 
within the National Patient Register (NPR); 
routinely collected  healthcare data 
Adult population at risk within 
database (whole Swedish 
population) 
Prevalence       
Present study 47.99 (43.09 to 53.46) England 2017 Retrospective Diagnostic code within the CPRD; routinely 
collected primary healthcare data 




17.3 (16.9 to 17.8) USA 2013-2018 Retrospective ≥ 2 diagnostic codes in electronic medical 
records, laboratories, practice management 
systems, or claims systems within Explorys 
Adult population at risk within 
database 
aAdjusted for age and sex 
bWhen standardised to European Standard Population: 1.4 (1.2 to 1.7) 
cWhen age standardised to European Standard Population: 0.68 (0.53 to 0.83) 
dAfter accounting for the estimated number of captured only in Pathology Register: 7.1 (6.5 to 7.7) 
 
